Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 8/2020

01-08-2020 | Tuberculosis | Review

Tuberculosis vaccine development: from classic to clinical candidates

Authors: Junli Li, Aihua Zhao, Jun Tang, Guozhi Wang, Yanan Shi, Lingjun Zhan, Chuan Qin

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 8/2020

Login to get access

Abstract

Bacillus Calmette-Guérin (BCG) has been in use for nearly 100 years and is the only licensed TB vaccine. While BCG provides protection against disseminated TB in infants, its protection against adult pulmonary tuberculosis (PTB) is variable. To achieve the ambitious goal of eradicating TB worldwide by 2050, there is an urgent need to develop novel TB vaccines. Currently, there are more than a dozen novel TB vaccines including prophylactic and therapeutic at different stages of clinical research. This literature review provides an overview of the clinical status of candidate TB vaccines and discusses the challenges and future development trends of novel TB vaccine research in combination with the efficacy of evaluation of TB vaccines, provides insight for the development of safer and more efficient vaccines, and may inspire new ideas for the prevention of TB.
Literature
1.
Correa-Macedo W et al (2019) The interplay of human and Mycobacterium tuberculosis Genomic Variability. Front Genet 18(10):865
2.
Mustafa AS (2005) Mycobacterial gene cloning and expression, comparative genomics, bioinformatics and proteomics in relation to the development of new vaccines and diagnostic reagents. Med Princ Pract 14(Suppl 1):27–34PubMed
3.
Hershkovitz I et al (2015) Tuberculosis origin: the Neolithic scenario. Tuberculosis (Edinb) 95(Suppl 1):S122–S126
4.
World Health Organization (2019) Global tuberculosis report 2019. WHO, Geneva
5.
World Health Organization (1994) TB: a global emergency, WHO report on the TB epidemic (WHO/TB/94.177). WHO, Geneva
6.
Styblo K, Meijer J, Sutherland I (1969) The transmission of tubercle bacilli: its trend in a human population. Bull World Health Organ 41(1):137–178PubMedPubMedCentral
7.
D'Arcy Hart P (2001) Historical declines in tuberculosis: nature, nurture and the biosocial model. Int J Tuberc Lung Dis 5(9):879PubMed
8.
9.
10.
DeWeerdt S (2013) Vaccines: an age-old problem. Nature 502(7470):S8–S9PubMed
11.
12.
Brosch R et al (2007) Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci U S A 104(13):5596–5601PubMedPubMedCentral
13.
Favorov M et al (2012) Comparative tuberculosis (TB) prevention effectiveness in children of Bacillus Calmette-Guerin (BCG) vaccines from different sources Kazakhstan. PLoS One 7(3):e32567PubMedPubMedCentral
14.
Mostowy S et al (2003) The in vitro evolution of BCG vaccines. Vaccine 21(27–30):4270–4274PubMed
15.
Trunz BB, Fine P, Dye C (2006) Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367(9517):1173–1180
16.
Blok BA et al (2015) Trained innate immunity as underlying mechanism for the long-term, nonspecific effects of vaccines. J Leukoc Biol 98(3):347–356PubMed
17.
Roth A et al (2006) Bacillus Calmette-Guerin vaccination and infant mortality. Expert Rev Vaccines 5(2):277–293PubMed
18.
19.
Rodrigues LC, Mangtani P, Abubakar I (2011) How does the level of BCG vaccine protection against tuberculosis fall over time? BMJ 343:d5974PubMed
20.
Mangtani P et al (2014) Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis 58(4):470–480PubMed
21.
Abubakar I et al (2013) Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guerin vaccination against tuberculosis. Health Technol Assess 17(37):1–372 v-vi PubMedPubMedCentral
22.
Andersen P, Doherty TM (2005) The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3(8):656–662PubMed
23.
Colditz GA et al (1994) Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271(9):698–702PubMed
24.
Fine PE (1995) Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346(8986):1339–1345PubMed
25.
Colditz GA et al (1995) The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96(1 Pt 1):29–35PubMed
26.
Gallant CJ et al (2010) Impact of age and sex on mycobacterial immunity in an area of high tuberculosis incidence. Int J Tuberc Lung Dis 14(8):952–959PubMed
27.
Trial of BCG vaccines in south India for tuberculosis prevention (1979) first report--Tuberculosis Prevention Trial. Bull World Health Organ 57(5):819–827
28.
Bulletin of the World Health Organization (1979) Trial of BCG vaccines in south India for tuberculosis prevention: first report. WHO, Geneva
29.
Harris DP et al (2005) Regulation of IFN-gamma production by B effector 1 cells: essential roles for T-bet and the IFN-gamma receptor. J Immunol 174(11):6781–6790PubMed
30.
Wagner M et al (2004) IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA. J Immunol 172(2):954–963PubMed
31.
Wang J et al (2004) Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 173(10):6357–6365PubMed
32.
Vordermeier HM et al (2009) Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect Immun 77(8):3364–3373PubMedPubMedCentral
33.
Dean G et al (2014) Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-priming and boosting with adenovirus or protein based vaccines. Vaccine 32(11):1304–1310PubMed
34.
Metcalfe HJ et al (2018) Ag85A-specific CD4+ T cell lines derived after boosting BCG-vaccinated cattle with Ad5-85A possess both mycobacterial growth inhibition and anti-inflammatory properties. Vaccine 36(20):2850–2854PubMedPubMedCentral
35.
Santosuosso M et al (2006) Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 74(8):4634–4643PubMedPubMedCentral
36.
Smaill F, Xing Z (2014) Human type 5 adenovirus-based tuberculosis vaccine: is the respiratory route of delivery the future? Expert Rev Vaccines 13(8):927–930PubMed
37.
Smaill F et al (2013) A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med 5(205):205ra134PubMed
38.
Jeyanathan M et al (2016) Induction of an immune-protective T-cell repertoire with diverse genetic coverage by a novel viral-vectored tuberculosis vaccine in humans. J Infect Dis 214(12):1996–2005PubMedPubMedCentral
39.
Stylianou E et al (2015) Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A. Vaccine 33(48):6800–6808PubMedPubMedCentral
40.
Hawkridge T et al (2008) Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis 198(4):544–552PubMedPubMedCentral
41.
Dockrell HM (2016) Towards new TB vaccines: what are the challenges? Pathog Dis 74(4):ftw016PubMed
42.
Lu JB et al (2016) Analysis of Koch phenomenon of Mycobacterium tuberculosis-infected guinea pigs vaccinated with recombinant tuberculosis vaccine AEC/BC02. Zhonghua Jie He He Hu Xi Za Zhi 39(7):524–528PubMed
43.
Perez-Martinez AP et al (2017) Conservation in gene encoding Mycobacterium tuberculosis antigen Rv2660 and a high predicted population coverage of H56 multistage vaccine in South Africa. Infect Genet Evol 55:244–250PubMed
44.
Lin PL et al (2012) The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J Clin Invest 122(1):303–314PubMed
45.
Suliman S et al (2019) Dose optimization of H56:IC31 vaccine for tuberculosis-endemic populations. A double-blind, placebo-controlled, dose-selection trial. Am J Respir Crit Care Med 199(2):220–231PubMed
46.
Luabeya AK et al (2015) First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults. Vaccine 33(33):4130–4140PubMed
47.
Orr MT et al (2014) A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93. PLoS One 9(1):e83884PubMedPubMedCentral
48.
Duthie MS et al (2014) Protection against Mycobacterium leprae infection by the ID83/GLA-SE and ID93/GLA-SE vaccines developed for tuberculosis. Infect Immun 82(9):3979–3985PubMedPubMedCentral
49.
Bertholet S et al (2010) A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med 2(53):53ra74PubMedPubMedCentral
50.
Baldwin SL et al (2012) The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol 188(5):2189–2197PubMedPubMedCentral
51.
Baldwin SL et al (2016) Protection and long-lived immunity induced by the ID93/GLA-SE vaccine candidate against a clinical Mycobacterium tuberculosis isolate. Clin Vaccine Immunol 23(2):137–147PubMedPubMedCentral
52.
Cha SB et al (2016) Pulmonary immunity and durable protection induced by the ID93/GLA-SE vaccine candidate against the hyper-virulent Korean Beijing Mycobacterium tuberculosis strain K. Vaccine 34(19):2179–2187PubMed
53.
Coler RN et al (2013) Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J Infect Dis 207(8):1242–1252PubMed
54.
Baldwin SL et al (2014) The ID93 tuberculosis vaccine candidate does not induce sensitivity to purified protein derivative. Clin Vaccine Immunol 21(9):1309–1313PubMedPubMedCentral
55.
Coler RN et al (2018) The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial. NPJ Vaccines 3:34PubMedPubMedCentral
56.
Penn-Nicholson A et al (2018) Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. Lancet Respir Med 6(4):287–298PubMed
57.
Homolka S, Ubben T, Niemann S (2016) High sequence variability of the ppE18 gene of clinical Mycobacterium tuberculosis complex strains potentially impacts effectivity of vaccine candidate M72/AS01E. PLoS One 11(3):e0152200PubMedPubMedCentral
58.
Montoya J et al (2013) A randomized, controlled dose-finding phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults. J Clin Immunol 33(8):1360–1375PubMedPubMedCentral
59.
Skeiky YA et al (1999) Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect Immun 67(8):3998–4007PubMedPubMedCentral
60.
Dillon DC et al (1999) Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect Immun 67(6):2941–2950PubMedPubMedCentral
61.
Al-Attiyah R et al (2004) In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis. Clin Exp Immunol 138(1):139–144PubMedPubMedCentral
62.
63.
Nabavinia MS et al (2012) Construction of an expression vector containing Mtb72F of Mycobacterium tuberculosis. Cell J 14(1):61–66PubMedPubMedCentral
64.
Skeiky YA et al (2004) Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 172(12):7618–7628PubMed
65.
Day CL et al (2013) Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in south African adults. Am J Respir Crit Care Med 188(4):492–502PubMedPubMedCentral
66.
Gillard P et al (2016) Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: a phase II randomised study. Tuberculosis (Edinb) 100:118–127
67.
Idoko OT et al (2014) Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial. Tuberculosis (Edinb) 94(6):564–578
68.
Kumarasamy N et al (2016) A randomized, controlled safety, and immunogenicity trial of the M72/AS01 candidate tuberculosis vaccine in HIV-positive Indian adults. Medicine (Baltimore) 95(3):e2459
69.
Leroux-Roels I et al (2013) Improved CD4(+) T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine 31(17):2196–2206PubMed
70.
Penn-Nicholson A et al (2015) Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting. Vaccine 33(32):4025–4034PubMedPubMedCentral
71.
Thacher EG et al (2014) Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial. AIDS 28(12):1769–1781PubMed
72.
Kumarasamy N et al (2018) Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: results from a phase II randomized controlled trial. Medicine (Baltimore) 97(45):S
73.
Van Der Meeren O et al (2018) Phase 2b controlled trial of M72/AS01E vaccine to prevent tuberculosis. N Engl J Med 379(17):1621–1634
74.
Cardona PJ (2006) RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb) 86(3–4):273–289
75.
Vilaplana C et al (2010) Double-blind, randomized, placebo-controlled phase I clinical trial of the therapeutical antituberculous vaccine RUTI. Vaccine 28(4):1106–1116PubMed
76.
Nell AS et al (2014) Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection. PLoS One 9(2):e89612PubMedPubMedCentral
77.
von Reyn CF et al (2010) Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 24(5):675–685
78.
Lahey T et al (2016) Immunogenicity and protective efficacy of the DAR-901 booster vaccine in a murine model of tuberculosis. PLoS One 11(12):e0168521PubMedPubMedCentral
79.
von Reyn CF et al (2017) Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: a randomized, controlled trial of DAR-901. PLoS One 12(5):e0175215
80.
Masonou T et al (2019) CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: a randomized, placebo-controlled trial. PLoS One 14(5):e0217091PubMedPubMedCentral
81.
Craig SR et al (2018) Altruism, scepticism, and collective decision-making in foreign-born U.S. residents in a tuberculosis vaccine trial. BMC Public Health 18(1):535PubMedPubMedCentral
82.
Sharma P et al (1999) Disabilities in multibacillary leprosy following multidrug therapy with and without immunotherapy with Mycobacterium w antileprosy vaccine. Int J Lepr Other Mycobact Dis 67(3):250–258PubMed
83.
Sharma P et al (2005) Immunoprophylactic effects of the anti-leprosy Mw vaccine in household contacts of leprosy patients: clinical field trials with a follow up of 8-10 years. Lepr Rev 76(2):127–143PubMed
84.
Sharma P et al (2000) Mycobacterium w vaccine, a useful adjuvant to multidrug therapy in multibacillary leprosy: a report on hospital based immunotherapeutic clinical trials with a follow-up of 1-7 years after treatment. Lepr Rev 71(2):179–192PubMed
85.
Guleria I, Mukherjee R, Kaufmann SH (1993) In vivo depletion of CD4 and CD8 T lymphocytes impairs Mycobacterium w vaccine-induced protection against M. tuberculosis in mice. Med Microbiol Immunol 182(3):129–135PubMed
86.
Gupta A et al (2012) Protective efficacy of Mycobacterium indicus pranii against tuberculosis and underlying local lung immune responses in guinea pig model. Vaccine 30(43):6198–6209PubMed
87.
Patel N, Deshpande MM, Shah M (2002) Effect of an immunomodulator containing Mycobacterium w on sputum conversion in pulmonary tuberculosis. J Indian Med Assoc 100(3):191–193PubMed
88.
Patel N, Trapathi SB (2003) Improved cure rates in pulmonary tuberculosis category II (retreatment) with mycobacterium w. J Indian Med Assoc 101(11):680 682 PubMed
89.
Groschel MI et al (2014) Therapeutic vaccines for tuberculosis--a systematic review. Vaccine 32(26):3162–3168PubMed
90.
Gonzalo-Asensio J et al (2017) MTBVAC: attenuating the human pathogen of tuberculosis (TB) toward a promising vaccine against the TB epidemic. Front Immunol 8:1803PubMedPubMedCentral
91.
Aguilo N et al (2016) MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice. Tuberculosis (Edinb) 96:71–74
92.
Marinova D et al (2017) MTBVAC from discovery to clinical trials in tuberculosis-endemic countries. Expert Rev Vaccines 16(6):565–576PubMed
93.
Spertini F et al (2015) Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. Lancet Respir Med 3(12):953–962PubMed
94.
World Health Organization (1995) Global tuberculosis program and global program on vaccine: statement on BCG revaccination for the prevention of tuberculosis. WHO, Geneva
95.
World Health Organization (2004) BCG vaccine. WHO position paper. WHO, Geneva
96.
World Health Organization (2018) BCG vaccines: WHO position paper-February 2018. WHO, Geneva
97.
World Health Organization (2007) Revised BCG vaccination guidelines for infants at risk for HIV infection. WHO, Geneva
98.
Husain AA et al (2011) Effect of repeat dose of BCG vaccination on humoral response in mice model. Indian J Exp Biol 49(1):7–10PubMed
99.
Husain AA et al (2015) Comparative evaluation of booster efficacies of BCG, Ag85B, and Ag85B peptides based vaccines to boost BCG induced immunity in BALB/c mice: a pilot study. Clin Exp Vaccine Res 4(1):83–87PubMedPubMedCentral
100.
Parlane NA et al (2014) Revaccination of cattle with bacille Calmette-Guerin two years after first vaccination when immunity has waned, boosted protection against challenge with Mycobacterium bovis. PLoS One 9(9):e106519PubMedPubMedCentral
101.
Kashyap RS et al (2010) Assessment of immune response to repeat stimulation with BCG vaccine using in vitro PBMC model. J Immune Based Ther Vaccines 8:3PubMedPubMedCentral
102.
Nemes E et al (2018) Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N Engl J Med 379(2):138–149PubMedPubMedCentral
103.
Nieuwenhuizen NE et al (2017) The recombinant Bacille Calmette-Guerin vaccine VPM1002: ready for clinical efficacy testing. Front Immunol 8:1147PubMedPubMedCentral
104.
Hamon MA et al (2012) Listeriolysin O: the Swiss army knife of Listeria. Trends Microbiol 20(8):360–368PubMed
105.
Shaughnessy LM et al (2006) Membrane perforations inhibit lysosome fusion by altering pH and calcium in Listeria monocytogenes vacuoles. Cell Microbiol 8(5):781–792PubMedPubMedCentral
106.
Reyrat JM, Berthet FX, Gicquel B (1995) The urease locus of Mycobacterium tuberculosis and its utilization for the demonstration of allelic exchange in Mycobacterium bovis bacillus Calmette-Guerin. Proc Natl Acad Sci U S A 92(19):8768–8772PubMedPubMedCentral
107.
Gordon AH, Hart PD, Young MR (1980) Ammonia inhibits phagosome-lysosome fusion in macrophages. Nature 286(5768):79–80PubMed
108.
Kaufmann SH et al (2014) The BCG replacement vaccine VPM1002: from drawing board to clinical trial. Expert Rev Vaccines 13(5):619–630PubMed
109.
Grode L et al (2013) Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine 31(9):1340–1348PubMed
110.
Loxton AG,Knaul JK,Grode L,Gutschmidt A,Meller C,Eisele B,Johnstone H,van der Spuy G,Maertzdorf J,Kaufmann SHE,Hesseling AC,Walzl G,Cotton MF., Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa. Clin Vaccine Immunol. 2017 Feb 6;24(2). pii: e00439-16. https://​doi.​org/​10.​1128/​CVI.​00439-16. Print 2017 Feb
111.
Lindenstrom T et al (2013) Control of chronic mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cells. J Immunol 190(12):6311–6319PubMed
112.
Grode L et al (2005) Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 115(9):2472–2479PubMedPubMedCentral
113.
Desel C et al (2011) Recombinant BCG DeltaureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis 204(10):1573–1584PubMedPubMedCentral
114.
Vogelzang A et al (2014) Central memory CD4+ T cells are responsible for the recombinant Bacillus Calmette-Guerin DeltaureC::hly vaccine's superior protection against tuberculosis. J Infect Dis 210(12):1928–1937PubMedPubMedCentral
115.
Gengenbacher M et al (2016) Post-exposure vaccination with the vaccine candidate Bacillus Calmette-Guerin DeltaureC::hly induces superior protection in a mouse model of subclinical tuberculosis. Microbes Infect 18(5):364–368PubMed
116.
Gengenbacher M, Nieuwenhuizen N, Vogelzang A, Liu H, Kaiser P, Schuerer S, Lazar D, Wagner I, Mollenkopf HJ, Kaufmann SH., Deletion of nuoG from the Vaccine Candidate Mycobacterium bovis BCG DeltaureC::hly Improves Protection against Tuberculosis. mBio.2016 May 24;7(3). pii: e00679-16. https://​doi.​org/​10.​1128/​mBio.​00679-16
117.
Velmurugan K et al (2013) Nonclinical development of BCG replacement vaccine candidates. Vaccines (Basel) 1(2):120–138
118.
Irwin SM et al (2005) Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect Immun 73(9):5809–5816PubMedPubMedCentral
119.
Brandt L et al (2004) The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun 72(11):6622–6632PubMedPubMedCentral
120.
Tsenova L et al (2006) Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis. Infect Immun 74(4):2392–2401PubMedPubMedCentral
121.
Reed SG et al (2009) Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci U S A 106(7):2301–2306PubMedPubMedCentral
122.
123.
124.
Commandeur S et al (2014) The in vivo expressed Mycobacterium tuberculosis (IVE-TB) antigen Rv2034 induces CD4+ T-cells that protect against pulmonary infection in HLA-DR transgenic mice and Guinea pigs. Vaccine 32(29):3580–3588PubMed
125.
126.
Lanoix JP et al (2015) Sterilizing activity of pyrazinamide in combination with first-line drugs in a C3HeB/FeJ mouse model of tuberculosis. Antimicrob Agents Chemother 60(2):1091–1096PubMed
127.
Lanoix JP et al (2015) Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis. Dis Model Mech 8(6):603–610PubMedPubMedCentral
128.
Aagaard C et al (2011) A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 17(2):189–194PubMed
129.
Jacobs RE et al (2015) Reactivation of pulmonary tuberculosis during cancer treatment. Int J Mycobacteriol 4(4):337–340PubMed
130.
Kashino SS et al (2008) Guinea pig model of Mycobacterium tuberculosis latent/dormant infection. Microbes Infect 10(14–15):1469–1476PubMedPubMedCentral
131.
Ordway DJ et al (2010) Evaluation of standard chemotherapy in the guinea pig model of tuberculosis. Antimicrob Agents Chemother 54(5):1820–1833PubMedPubMedCentral
132.
Clark S et al (2014) Animal models of tuberculosis: guinea pigs. Cold Spring Harb Perspect Med 5(5):a018572PubMed
133.
Converse PJ et al (1996) Cavitary tuberculosis produced in rabbits by aerosolized virulent tubercle bacilli. Infect Immun 64(11):4776–4787PubMedPubMedCentral
134.
Zhang G et al (2010) Evaluation of mycobacterial virulence using rabbit skin liquefaction model. Virulence 1(3):156–163PubMedPubMedCentral
135.
Dannenberg AM Jr (2009) Liquefaction and cavity formation in pulmonary TB: a simple method in rabbit skin to test inhibitors. Tuberculosis (Edinb) 89(4):243–247
136.
Sun H et al (2012) Effects of immunomodulators on liquefaction and ulceration in the rabbit skin model of tuberculosis. Tuberculosis (Edinb) 92(4):345–350
137.
138.
Manabe YC et al (2008) The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. Tuberculosis (Edinb) 88(3):187–196
139.
Rahyussalim AJ et al (2016) New bone formation in tuberculous-infected vertebral body defect after administration of bone marrow stromal cells in rabbit model. Asian Spine J 10(1):1–5PubMedPubMedCentral
140.
Scanga CA et al (1999) Reactivation of latent tuberculosis: variations on the Cornell murine model. Infect Immun 67(9):4531–4538PubMedPubMedCentral
141.
Izzo AA et al (2015) A novel MVA-based multiphasic vaccine for prevention or treatment of tuberculosis induces broad and multifunctional cell-mediated immunity in mice and primates. PLoS One 10(11):e0143552
142.
143.
Phuah J et al (2016) Effects of B cell depletion on early Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun 84(5):1301–1311PubMedPubMedCentral
144.
Lin PL et al (2009) Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect Immun 77(10):4631–4642PubMedPubMedCentral
145.
Diedrich CR et al (2010) Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. PLoS One 5(3):e9611PubMedPubMedCentral
146.
Kupferschmidt K (2011) Infectious disease. Taking a new shot at a TB vaccine. Science 334(6062):1488–1490PubMed
147.
McShane H et al (2004) Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10(11):1240–1244PubMed
148.
Verreck FA et al (2009) MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One 4(4):e5264PubMedPubMedCentral
149.
Beveridge NE et al (2007) Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 37(11):3089–3100PubMedPubMedCentral
150.
Minassian AM et al (2011) A phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults. BMJ Open 1(2):e000223PubMedPubMedCentral
151.
Odutola AA et al (2012) A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants. Vaccine 30(38):5591–5594PubMed
152.
Pathan AA et al (2012) Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults. Vaccine 30(38):5616–5624PubMedPubMedCentral
153.
Sander CR et al (2009) Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med 179(8):724–733PubMedPubMedCentral
154.
Scriba TJ et al (2010) Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol 40(1):279–290PubMedPubMedCentral
155.
Scriba TJ et al (2011) Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J Infect Dis 203(12):1832–1843PubMed
156.
Scriba TJ et al (2012) A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med 185(7):769–778PubMedPubMedCentral
157.
Tameris MD et al (2013) Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381(9871):1021–1028PubMedPubMedCentral
158.
Cole ST et al (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393(6685):537–544PubMed
159.
Kaufmann SH (2011) Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect Dis 11(8):633–640PubMed
160.
161.
Barker LF et al (2009) Tuberculosis vaccine research: the impact of immunology. Curr Opin Immunol 21(3):331–338PubMed
162.
163.
Williams A, Hall Y, Orme IM (2009) Evaluation of new vaccines for tuberculosis in the guinea pig model. Tuberculosis (Edinb) 89(6):389–397
164.
Reed SG et al (2003) Prospects for a better vaccine against tuberculosis. Tuberculosis (Edinb) 83(1–3):213–219
165.
Fennelly KP et al (2012) Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis. Am J Respir Crit Care Med 186(5):450–457PubMedPubMedCentral
Metadata
Title
Tuberculosis vaccine development: from classic to clinical candidates
Authors
Junli Li
Aihua Zhao
Jun Tang
Guozhi Wang
Yanan Shi
Lingjun Zhan
Chuan Qin
Publication date
01-08-2020
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 8/2020
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-020-03843-6

Other articles of this Issue 8/2020

European Journal of Clinical Microbiology & Infectious Diseases 8/2020 Go to the issue

Brief Report

A family cluster of severe acute respiratory syndrome coronavirus 2 infections

Original Article

Performance and ease of use of a molecular point-of-care test for influenza A/B and RSV in patients presenting to primary care

Original Article

Significant shifts in the distribution of vaccine capsular polysaccharide types and rates of antimicrobial resistance of perinatal group B streptococci within the last decade in St. Petersburg, Russia

Original Article

Molecular epidemiology of invasive Haemophilus influenzae disease in Portugal: an update of the post-vaccine period, 2011–2018

Brief Report

Ultrarapid diagnosis, microscope imaging, genome sequencing, and culture isolation of SARS-CoV-2

Original Article

Viruses and atypical bacteria in the respiratory tract of immunocompromised and immunocompetent patients with airway infection

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits